{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:26Z","timestamp":1790991626751,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101117","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:24:32Z","timestamp":1695212672000},"page":"101117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-9529","authenticated-orcid":false,"given":"John W.","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur H.M.","family":"Burghes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf W.","family":"van Olden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi R.","family":"Adhikary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Dilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101117_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","article-title":"Controlling AAV tropism in the nervous system with natural and engineering capsids","volume":"1382","author":"Castle","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2023.101117_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101117_bib3","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9","volume":"86","author":"DiMattia","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.101117_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib5","first-page":"31","article-title":"Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders","volume":"11","author":"Jablonka","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.omtm.2023.101117_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.726468","article-title":"Recombinant adeno-associated virus serotype 9 gene therapy in spinal muscular atrophy","volume":"12","author":"Kotulska","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.101117_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.101117_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2023.101117_bib10","first-page":"152","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen","year":"2014","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase 3 SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase 3 SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101117_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib22","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.vaccine.2020.12.049","article-title":"Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies","volume":"40","author":"Albrecht","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2023.101117_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-019-0392-8","article-title":"The repertoire of maternal anti-viral antibodies in human newborns","volume":"25","author":"Pou","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib24","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1016\/S0264-410X(03)00336-0","article-title":"Transfer of antibody via mother\u2019s milk","volume":"21","author":"Van de Perre","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2023.101117_bib25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.omtm.2023.101117_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral immune response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.101117_bib27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omtm.2023.101117_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/humc.2017.109","article-title":"Differential prevalence of antibodies against adeno-associated virus in healthy children and parents with mucopolysaccharidosis III: perspective for AAV-mediated gene therapy","volume":"28","author":"Fu","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101117_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.omtm.2023.101117_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1089\/hum.2022.054","article-title":"Prevalence of anti-AAV9 antibodies in adult patients with spinal muscular atrophy","volume":"33","author":"Stolte","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2023.101117_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omtm.2023.101117_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101117_bib35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib36","series-title":"Prescribing Information","year":"2021"},{"key":"10.1016\/j.omtm.2023.101117_bib37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: A nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.101117_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.101117_bib39","first-page":"39","article-title":"Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs","volume":"28","author":"Ballreich","year":"2022","journal-title":"J.\u00a0Manag. Care Spec. Pharm."},{"key":"10.1016\/j.omtm.2023.101117_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.27261","article-title":"Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.101117_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.684134","article-title":"2020\u00a0Update to spinal muscular atrophy management in Saudi Arabia","volume":"9","author":"Bashiri","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.omtm.2023.101117_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.omtm.2023.101117_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.101117_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements, and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.101117_bib45","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtm.2023.101117_bib46","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2023.101117_bib47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","article-title":"Combination therapy with nusinersen and AVXS-101 in SMA type 1","volume":"93","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2023.101117_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105488","article-title":"Dual SMN inducing therapies can rescue survival and motor function in symptomatic \u03947SMA mice","volume":"159","author":"Kray","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2023.101117_bib49","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/mus.27648","article-title":"Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy","volume":"66","author":"Ferrante","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.101117_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41434-022-00339-0","article-title":"Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec \u2013 routine care evidence","volume":"30","author":"Aharoni","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adenoassociated virus (AAV) types 1,2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib52","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2023.101117_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101117_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41434-022-00353-2","article-title":"Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials","volume":"30","author":"Cao","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/hum.2021.243","article-title":"Higher seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States","volume":"33","author":"Khatri","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101117_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ijns7030033","article-title":"Landscape of spinal muscular atrophy newborn screening in the United States: 2018\u20132021","volume":"7","author":"Hale","year":"2021","journal-title":"Int. J. Neonatal Screen."}],"container-title":["Molecular Therapy Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:07:51Z","timestamp":1756138071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":57,"alternative-id":["S2329050123001560"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101117","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101117"}}